The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 15, 2020

Filed:

Dec. 23, 2019
Applicant:

The Regents of the University of Michigan, Ann Arbor, MI (US);

Inventors:

Brian D. Athey, Ann Arbor, MI (US);

Ari Allyn-Feuer, Ann Arbor, MI (US);

Gerald A. Higgins, Ann Arbor, MI (US);

James S. Burns, Ann Arbor, MI (US);

Alexandr Kalinin, Ann Arbor, MI (US);

Brian Pauls, Ann Arbor, MI (US);

Alex Ade, Ann Arbor, MI (US);

Narathip Reamaroon, Ann Arbor, MI (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 10/60 (2018.01); A61K 31/37 (2006.01); G16H 50/70 (2018.01); G16B 30/00 (2019.01); G16B 40/00 (2019.01); G16B 20/00 (2019.01); G06N 3/08 (2006.01);
U.S. Cl.
CPC ...
G16H 50/20 (2018.01); A61K 31/37 (2013.01); G06N 3/08 (2013.01); G16B 20/00 (2019.02); G16B 30/00 (2019.02); G16B 40/00 (2019.02); G16H 10/60 (2018.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01);
Abstract

For patients who exhibit or may exhibit primary or comorbid disease, pharmacological phenotypes may be predicted through the collection of panomic data over a period of time. A machine learning engine may generate a statistical model based on training data from training patients to predict pharmacological phenotypes, including drug response and dosing, drug adverse events, disease and comorbid disease risk, drug-gene, drug-drug, and polypharmacy interactions. Then the model may be applied to data for new patients to predict their pharmacological phenotypes, and enable decision making in clinical and research contexts, including drug selection and dosage, changes in drug regimens, polypharmacy optimization, monitoring, etc., to benefit from additional predictive power, resulting in adverse event and substance abuse avoidance, improved drug response, better patient outcomes, lower treatment costs, public health benefits, and increases in the effectiveness of research in pharmacology and other biomedical fields.


Find Patent Forward Citations

Loading…